ASCO GU 2024

Cabo + IO: Interesting but not practice changing?!

Is "more" always better?

BRCAAway - practice changing or hypothesis generating data?

Combination vs. monotherapy - a great new option for high-risk patients

Higher radiation is effective in high-risk PCA

Evaluating the recombination-repair mutations in patients with mCRPC

Still a difficult time for androgenic inhibitors in mCRPC

BRCAaway - PARP combination study

Relugolix combined with androgen signaling in real word experience

Combination of cabozantinib & checkpoint inhibitor

Dose de-escalation in different ways

Olaparib + Arbiraterone better compared to either alone

Insights and news for mCRPC

Quality of life under intensive therapy

Combination NHT + PARP makes sense

What about the clinical benefit?

Stockholm3 validated in multiethnic cohort

Therapy Intensification Still Neglected in mHSPC

Salvage radiation with anti-androgen superior to radiation alone

Long-term dose escalation - Therapy in high-risk prostate cancers

Localized PCa - news for radiotherapy and biochemical recurrence

Further testing before olaparib combination

Enzalutamide therapy as option for biochemical recurrence

Cognitive function in ART treatment

Gleason 3+3 - cancer or not?

First positive study of IO therapy in mCRPC

Post-RP salvage radyoterapi hormonoterapi ile konbine edilmeli

Kognitiv påverkan av abirateron och enzalutamid?

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi)

Orta riskli PCa da RARP sirasinda LND dan vazgecilebilir mi?

Gleason 3+3 ska vi kalla de cancer eller inte?

Kombination av cabozantinib och immunterapi

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO GU '24

Une période encore difficile pour les inhibiteurs androgéniques dans le cancer de la prostate métastatique résistant à la castration.

BRCAAway - PARP hämmare, abiraterone eller i kombination

SEPTA calismasi: Stockholm3 un multietnik hasta grubunda validasyonu

ADC + ICI: new data for platinum-refractory bladder cancaer patients

Advances in (neo)-adjuvant treatment in urothelial cancer

New standard of care, but still open questions!

The emerging field of biomarkers in bladder cancer

Another success for an ICI?

Adjuvant therapy in urothelial carcinoma : is the equation resolved?

Should we start forgetting the Galsky Criteria in advanced urothelial carcinoma?

EV + Pembro new first-line standard in localized metastatic bladder cancer

Biomarker update

HER2 and bladder cancer

Update on EV-302

Highlights in bladder cancer at ASCO GU24

ASCO GU24 - Highlights in Bladder cancer

EV as standard in 3rd line mUC

MIBC: adjuvant PD1 - all set?!

Perioperative adjuvant therapy in urothelial cancer

Adjuvant Nivolumab Shows Promise in Boosting Long-Term Survivorship for High-Risk Muscle-Invasive Urothelial Carcinoma

Update M1 urothelial cancer

Pembrolizumab adjuvant in bladder cancer

¿Deberíamos empezar a olvidarnos de los Criterios de Galsky en cancer urotelial avanzado?

Novedades sobre EV-302

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Encore un succès pour une ICI ?

Terapia adyuvante perioperatoria en el cáncer de vejiga

Tratamiento adyuvante en cancer urotelial: ¿está resuelta la ecuación?

Subcutaneous vs. intravenous application: ready for everyday clinics?

Trial updates at ASCO GU24: Are the follow-up data confirmatory?

Adjuvant therapy in kidney cancer: Is immunotherapy the answer?

No surprise with the QoL data

Better QoL with Belzutifan

Tumorburden and outcome

Belzutifan: Updates on QoL

Practice changing adjuvant therapy?!

Long-term outcome

Perioperative treatment in renal cell carcinoma - did we close the circle?

Long-Term Data on NIVO+IPI in aRCC

Cabozantinib Plus Atezolizumab in Adrenocortical Carcinoma Falls Short of Expectations, Emphasizing Ongoing Need for Treatment Innovations

Durable effects of Ipi-Nivo

Overall survival benefit - Pembro after surgery

Long-term follow-up of first-line trials

Highlights in kidney cancer at ASCO GU24

ASCO GU24 - Highlights in renal cell carcinoma

Subcutaneous Nivolumab Matches IV Formulation in Clear Cell Renal Cell Carcinoma, Paving the Way for Enhanced Therapy Delivery and Safety

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark CheckMate-9ER Trial: Prolonged Efficacy and Safety Reinforce Standard of Care in Advanced Renal Cell Carcinoma

Tratamiento perioperatorio en cancer renal: ¿Hemos cerrado el círculo?

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24